Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

NCT05985681

Status	RECRUITING
Phase	Phase 1
Sponsor	National Cancer Institute (NCI)
Enrollment	18 participants

Key Eligibility Criteria

Inclusion (18)

- Women, age 18 - 60 years. Because no dosing or adverse event (AE) data is currently available for the use of RG1-VLP in humans, children and adolescents are excluded from this study
- White blood cell (WBC) between 3000/mm\^3 - institutional upper limit of normal
- Hemoglobin (Hgb) between 10 g/dl - institutional upper limit of normal
- Platelets \>= 100,000/mm\^3
- Serum creatinine within institutional normal limits

... and 13 more (see full listing online)

Exclusion (21)

- History of any of the following:
- Prior or current genital warts
- Treatment for anogenital intraepithelial neoplasia (cervical intraepithelial neoplasia \[CIN\], anal intraepithelial neoplasia \[AIN\], vaginal intraepithelial neoplasia \[VAIN\], vulvar intraepithelial neoplasia \[VIN\])
- Systemic cancer treatment within the prior year
- History of anaphylaxis to vaccines

... and 16 more (see full listing online)

Locations (5 total)

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Staten Island University Hospital, Staten Island, New York, United States
... and 2 more locations